High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allograft recipients according to American diabetes association criteria

被引:37
作者
Cho, YM
Park, KS
Jung, HS
Jeon, HJ
Ahn, C
Ha, J
Kim, SJ
Rhee, BD
Kim, SY
Lee, HK
机构
[1] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea
[3] Inje Univ Med Coll, Dept Internal Med, Seoul, South Korea
关键词
D O I
10.2337/diacare.26.4.1123
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-The incidence of posttransplantation diabetes mellitus (PTDM) has been reported to vary according to different study populations or different definitions. In this study, using American Diabetes Association criteria, the incidence and clinical characteristics of PTDM in Korean renal allograft recipients undergoing tacrolimus-based immunosuppression were examined. Research Design and Methods-A total of 21 patients taking tacrolimus as primary immunosuppressant were recruited and tested with a serial 75-g oral glucose tolerance test at 0, 1, 3, and 6 months after renal transplantation. Results-The cumulative incidence of PTDM was 52.4% at <LF>month and 57.1% at 3 and 6 months. The baseline characteristics of the PTDM group were old age (especially >40 years), a high BMI, a high fasting glucose level, a high plasma insulin level, and increased insulin resistance. Among these parameters, old age was the only independent risk factor. The insulin secretory capacity in the PTDM group was maximally suppressed 3 months after transplantation. Thereafter, it was gradually restored along with dose reduction of tacrolimus. Conclusions-Routine screening for PTDM is necessary in patients over 40 years of age who are undergoing a relatively higher dose tacrolimus therapy during the early course of postrenal transplantation.
引用
收藏
页码:1123 / 1128
页数:6
相关论文
共 39 条
[1]  
AHN KJ, 1992, TRANSPLANT P, V24, P1581
[2]  
[Anonymous], 1996, DIABETES, V45, P1289
[3]   Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: Role of hepatitis C infection [J].
Baid, S ;
Tolkoff-Rubin, N ;
Farrell, ML ;
Delmonico, FL ;
Williams, WW ;
Hayden, D ;
Ko, D ;
Cosimi, AB ;
Pascual, M .
TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) :1771-1773
[4]   The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study [J].
Charles, MA ;
Eschwege, E ;
Thibult, N ;
Claude, JR ;
Warnet, JM ;
Rosselin, GE ;
Girard, J ;
Balkau, B .
DIABETOLOGIA, 1997, 40 (09) :1101-1106
[5]   A case showing complete insulin independence after severe diabetic ketoacidosis associated with tacrolimus treatment [J].
Cho, YM ;
Park, KS ;
Jung, HS ;
Kim, YS ;
Kim, SY ;
Lee, HK .
DIABETES CARE, 2002, 25 (09) :1664-1664
[6]   Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients [J].
Ciancio, G ;
Burke, GW ;
Suzart, K ;
Roth, D ;
Kupin, W ;
Rosen, A ;
Olson, L ;
Esquenazi, V ;
Miller, J .
TRANSPLANTATION, 2002, 73 (07) :1100-1106
[7]  
FUKAO K, 1993, TRANSPLANT P, V25, P649
[8]   Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients [J].
Furth, S ;
Neu, A ;
Colombani, P ;
Plotnick, L ;
Turner, ME ;
Fivush, B .
PEDIATRIC NEPHROLOGY, 1996, 10 (01) :64-66
[9]  
Gavin JR, 1997, DIABETES CARE, V20, P1183
[10]   MORPHOLOGICAL AND FUNCTIONAL-CHANGES OF ISLETS OF LANGERHANS IN FK506-TREATED RATS [J].
HIRANO, Y ;
FUJIHIRA, S ;
OHARA, K ;
KATSUKI, S ;
NOGUCHI, H .
TRANSPLANTATION, 1992, 53 (04) :889-894